Results 191 to 200 of about 12,862 (201)

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

Lancet, The, 2013
Kris V Kowdley, Eric Lawitz, Mitchell N Davis   +2 more
exaly  

Sofosbuvir + simeprevir dominates sofosbuvir + ribavirin

PharmacoEconomics & Outcomes News, 2014
openaire   +1 more source

Ledipasvir/sofosbuvir/peginterferon/ribavirin/sofosbuvir

Reactions Weekly, 2016
openaire   +1 more source

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Lancet, The, 2014
Eric Lawitz, Mark S Sulkowski, Reem Ghalib   +2 more
exaly  

Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir

Reactions Weekly
openaire   +1 more source

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Clinical Pharmacokinetics, 2016
Polina German, Anita Mathias, Diana Brainard   +2 more
exaly  

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related Child's Class A Cirrhosis

Gastroenterology, 2015
Brian L Pearlman
exaly  

Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C

Drugs, 2014
exaly  

Ledipasvir/Sofosbuvir: A Review of Its Use in Chronic Hepatitis C

Drugs, 2015
exaly  

Sofosbuvir

openaire   +1 more source